David Domzalski is CEO & President at VYNE Therapeutics Inc. (VYNE). They have made 13 open-market trades across 2 companies since 2018, most recently 2026-07-23.
CIK 0001727794
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $207K since 2020, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VYNE | BUY | 2020-09-08 | 2020-09-08 | $1.38 | $207K | +23.6% | +30.4% | +14.2% |
| FOMX | SELL | 2019-07-01 | 2019-07-03 | $2.35 | $8K | +1.3% | +5.2% | +27.2% |
| FOMX | SELL | 2019-04-01 | 2019-04-03 | $3.75 | $19K | -5.4% | -16.5% | -40.9% |
| FOMX | SELL | 2018-12-03 | 2018-12-06 | $4.05 | $275 | -15.2% | -5.4% | -11.0% |
| FOMX | SELL | 2018-11-19 | 2018-11-20 | $3.90 | $20K | +7.9% | -5.3% | -2.6% |
| FOMX | SELL | 2018-11-08 | 2018-11-13 | $4.58 | $9K | -3.3% | +0.5% | -10.8% |
| FOMX | SELL | 2018-10-01 | 2018-10-02 | $5.81 | $3K | -5.5% | -19.0% | -34.4% |
| FOMX | SELL | 2018-09-04 | 2018-09-06 | $5.67 | $380 | -9.6% | -13.2% | -25.3% |
| FOMX | SELL | 2018-08-08 | 2018-08-09 | $5.68 | $47K | +4.7% | +6.8% | -19.9% |
| FOMX | SELL | 2018-07-02 | 2018-07-03 | $5.10 | $3K | +11.6% | +12.9% | +13.1% |
| FOMX | SELL | 2018-06-01 | 2018-06-04 | $5.26 | $352 | +5.0% | -0.2% | +9.7% |
| FOMX | SELL | 2018-04-02 | 2018-04-04 | $5.08 | $3K | +7.1% | -0.4% | +0.8% |
| FOMX | SELL | 2018-03-01 | 2018-03-05 | $5.95 | $393 | -6.1% | -12.2% | -9.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.